The volume of combination products or submissions with jurisdictional ambiguity coming through FDA has remained relatively constant in the past five to six years, but the number of formal consultations between FDA product review centers has doubled during the same period.
The trend reflects a growing complexity in the products coming through the agency and in particular confusions over how to handle human factors issues for many combination products, explains Thinh Nguyen, director of the agency's